Replies to post #1659 on Ligand Pharmaceuticals Inc (LGND)

[$theDDmessiah]

This LGNDZ. is a RocheCVR LGNYZ is a GENERALCVR

We at LGNYZ get funding
General CVR. The General CVR Agreement entitles each holder of a General CVR to receive a pro rata portion of cash payments equal to the shortfall, if any, from defined spending thresholds of Ligand’s funding of further research and development of drug development programs acquired from Metabasis. The basic threshold is $8 million of funding within the first 42 months after the Merger. A secondary threshold (which shall be waived in certain circumstances) is $7 million of funding within the first 30 months after the Merger.